349 related articles for article (PubMed ID: 36290903)
1. Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress.
Gadaleta-Caldarola G; Rizzo A; Dadduzio V; Lombardi L; Gadaleta-Caldarola A; Infusino S; Cusmai A; Citrigno C; Palmiotti G
Curr Oncol; 2022 Oct; 29(10):7925-7931. PubMed ID: 36290903
[TBL] [Abstract][Full Text] [Related]
2. Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma.
Rizzo A; Ricci AD; Brandi G
Cancer Treat Res Commun; 2021; 27():100337. PubMed ID: 33611090
[TBL] [Abstract][Full Text] [Related]
3. Pemigatinib: A Review in Advanced Cholangiocarcinoma.
Frampton JE
Target Oncol; 2024 Jan; 19(1):107-114. PubMed ID: 38206555
[TBL] [Abstract][Full Text] [Related]
4. Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors.
Rizzo A
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34066684
[TBL] [Abstract][Full Text] [Related]
5. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
Aitcheson G; Mahipal A; John BV
Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
[No Abstract] [Full Text] [Related]
6. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
King G; Javle M
Curr Oncol Rep; 2021 Jul; 23(9):108. PubMed ID: 34269915
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management.
Chakrabarti S; Finnes HD; Mahipal A
Expert Opin Drug Metab Toxicol; 2022 Jan; 18(1):85-98. PubMed ID: 35129006
[TBL] [Abstract][Full Text] [Related]
8. Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future.
Rizzo A; Ricci AD; Cusmai A; Acquafredda S; De Palma G; Brandi G; Palmiotti G
Curr Oncol; 2022 Jan; 29(2):551-564. PubMed ID: 35200550
[TBL] [Abstract][Full Text] [Related]
9. Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications.
Amadeo E; Rossari F; Vitiello F; Burgio V; Persano M; Cascinu S; Casadei-Gardini A; Rimini M
Expert Rev Clin Pharmacol; 2023; 16(7):631-642. PubMed ID: 37387533
[TBL] [Abstract][Full Text] [Related]
10. The future of fibroblast growth factor receptor inhibitors and mechanisms of resistance for cholangiocarcinoma.
Ruff SM; Roychowdhury S; Pawlik TM
Expert Opin Pharmacother; 2023 May; 24(7):779-788. PubMed ID: 37042129
[TBL] [Abstract][Full Text] [Related]
11. Does aspirin use influence hepatocellular carcinoma and cholangiocarcinoma prognosis?
Stefanini B; Tonnini M; Marseglia M; Tovoli F
Expert Rev Anticancer Ther; 2022 Sep; 22(9):887-889. PubMed ID: 35866267
[No Abstract] [Full Text] [Related]
12. Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology.
Capuozzo M; Santorsola M; Landi L; Granata V; Perri F; Celotto V; Gualillo O; Nasti G; Ottaiano A
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499450
[TBL] [Abstract][Full Text] [Related]
13. Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma.
Wu Q; Ellis H; Siravegna G; Michel AG; Norden BL; Fece de la Cruz F; Balasooriya ER; Zhen Y; Silveira VS; Che J; Corcoran RB; Bardeesy N
Clin Cancer Res; 2024 Jan; 30(1):198-208. PubMed ID: 37843855
[TBL] [Abstract][Full Text] [Related]
14. Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion.
Storandt MH; Jin Z; Mahipal A
Expert Rev Anticancer Ther; 2022 Dec; 22(12):1265-1274. PubMed ID: 36408971
[TBL] [Abstract][Full Text] [Related]
15. Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma.
Saborowski A; Vogel A; Segatto O
Trends Cancer; 2022 Feb; 8(2):83-86. PubMed ID: 34840108
[TBL] [Abstract][Full Text] [Related]
16. Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors.
Wu T; Jiang X; Zhang X; Wu B; Xu B; Liu X; Zheng L; Wang Y
Cancer Control; 2021; 28():1073274821989314. PubMed ID: 33618536
[TBL] [Abstract][Full Text] [Related]
17. Favorable Management of Repeated Serous Retinal Detachment with Continued Tumor Response in a Patient with Intrahepatic Cholangiocarcinoma during Treatment with Pemigatinib.
Yukutake M; Sekito T; Yamakita I; Itakura H; Kabu K; Nagata S
Intern Med; 2023 Apr; 62(8):1151-1155. PubMed ID: 35945011
[TBL] [Abstract][Full Text] [Related]
18. A drug safety evaluation of pemigatinib for advanced cholangiocarcinoma.
Uson PLS; Bearss J; Babiker HM; Borad M
Expert Opin Drug Saf; 2023; 22(8):637-641. PubMed ID: 37363820
[TBL] [Abstract][Full Text] [Related]
19. Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.
Parisi A; Delaunay B; Pinterpe G; Hollebecque A; Blanc JF; Bouattour M; Assenat E; Ben Abdelghani M; Sarabi M; Niger M; Vivaldi C; Mandalà M; Palloni A; Bensi M; Garattini SK; Tougeron D; Combe P; Salati M; Rimini M; Cella CA; Tucci M; Diana A; Mori E; Longarini R; Artru P; Roth G; Evesque L; Vienne A; Turpin A; Hiret S; Bourgeois V; Herve C; Paulon R; Stacoffe M; Malka D; Neuzillet C; Edeline J; Lievre A; Guimbaud R; Chapda MCP; Rimassa L; Giampieri R; Valle J; Berardi R; Fares N
Eur J Cancer; 2024 Mar; 200():113587. PubMed ID: 38340384
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy for hepatocellular carcinoma and cholangiocarcinoma.
Chung V
Surg Oncol Clin N Am; 2015 Jan; 24(1):187-98. PubMed ID: 25444475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
